Diadexus Inc. (GREY:DDXS)

Tuesday, May 7, 2013 | Web News
First Quarter 2013 Results Total revenues for the first quarter 2013 were $5.6 million, a 12% increase over $4.9 million reported...
Thursday, February 16, 2012 | Web News
Our blog note from 2/16/2012 Healthcare company with primary focus in heart disease. They possess the only FDA approved blood test, predicting heart disease and...
See All Research...
diaDexus, Inc., based in South San Francisco, California, is focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease. The company's PLAC Test for Lp-PLA2 is the only blood test cleared by the FDA to aid in predicting risk for both coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States.

Web site: http://www.diaDexus.com.

Last updated February 16, 2012


Market Data powered by QuoteMedia. Terms of Use